Butterfly Network to Participate in 2026 J.P. Morgan Healthcare Conference
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 18 2025
0mins
Source: Newsfilter
- Conference Participation: Butterfly Network will participate in the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2026, in San Francisco, showcasing its innovations in digital health, which is expected to attract investor interest.
- Executive Attendance: Company executives Joseph DeVivo, John Doherty, and Megan Carlson will host investor meetings to present their latest ultrasound technology, further enhancing the company's market visibility in the medical imaging sector.
- Live Webcast: Butterfly will provide a live webcast of its presentation on January 15, with replay available until February 15, enhancing engagement and transparency with investors.
- Technological Innovation: Butterfly's ultrasound technology has received multiple awards, including the Best Medical Technology at the 2024 Prix Galien USA, demonstrating its leadership and ongoing innovation in the medical imaging field.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like BFLY with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on BFLY
Wall Street analysts forecast BFLY stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BFLY is 4.25 USD with a low forecast of 4.00 USD and a high forecast of 4.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.310
Low
4.00
Averages
4.25
High
4.50
Current: 4.310
Low
4.00
Averages
4.25
High
4.50
About BFLY
Butterfly Network, Inc. is a healthcare company focused on medical imaging with its Ultrasound-on-Chip semiconductor technology and ultrasound software solutions. The Company's solution, leveraging its Ultrasound-on-Chip technology, enables the practical application of ultrasound information into the clinical workflow. Its product portfolio includes a combination of hardware and software, including Butterfly iQ3, Butterfly iQ+, Butterfly iQ+ Bladder, and Butterfly iQ+ Vet devices, software subscriptions, and professional services. It offers cloud-based software solutions to healthcare systems, teleguidance, in-app educational tutorials as well as its ScanLab education-only app, formal education programs through its Butterfly Academy software and Butterfly Certified courses, as well as professional services for large scale deployments. Its devices are commercially available to trained healthcare practitioners in areas including, but not limited to, parts of Africa, Asia, and Australia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rapid Growth in Cardiac AI Diagnostics Market
- Market Surge: The global medical imaging market reached $45.5 billion in 2026, indicating a significant shift towards AI-native precision, particularly due to the rising demand for heart monitoring in cancer treatments.
- Rise of Cardiac AI Diagnostics: The cardiac AI diagnostics sector hit $2.22 billion in 2026, driven by the urgent need for continuous imaging to monitor heart dysfunction, enhancing the company's competitive edge in the medical technology market.
- Strategic Partnership Enhances Value: Ventripoint's collaboration with Summit Sciences to develop ROI models illustrates how hospitals can achieve cost savings through technological improvements, further solidifying its market position in cardiac care.
- Executive Appointment Fuels Growth: The appointment of David Swetlow as CFO, with extensive experience in medical technology, is expected to accelerate market adoption and revenue growth, driving the execution of the company's commercial strategy.
Continue Reading
Rapid Growth in Cardiac AI Diagnostics Market
- Market Size Surge: The global medical imaging market reached $45.5 billion in 2026, indicating a significant shift towards AI-driven precision, with the cardiac AI diagnostics sector hitting $2.22 billion, reflecting a critical demand for continuous imaging.
- Technological Innovation: VentriPoint Diagnostics is transforming standard 2D ultrasound images into MRI-level 3D heart models, significantly reducing costs and complexity, which is expected to drive rapid growth in its subscription business.
- Surge in Investment Demand: The company recently doubled its private placement from $500,000 to $1 million, with funds allocated for commercialization and market expansion, showcasing strong investor confidence in its technology and market potential.
- Strategic Partnership: VentriPoint's collaboration with Summit Sciences to develop ROI models aims to demonstrate the economic value of its technology to hospitals, further solidifying its market position in medical imaging.
Continue Reading